Affiliation:
1. Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA.
Abstract
Two new fluorinated oxazolidinones, U-100592 and U-100766, were evaluated against more than 659 gram-positive and -negative organisms and compared with glycopeptides, erythromycin, clindamycin, clinafloxacin, and chloramphenicol. U-100592 and U-100766 were usually equally potent, but the MICs at which 90% of the isolates are inhibited (MIC90s) of U-100592 for some staphylococci and enterococci were slightly lower than those of U-100766 (1 versus 2 micrograms/ml). The MIC90 of U-100592 and U-100766 for oxacillin-resistant Staphylococcus aureus was 2 micrograms/ml, the same as observed for oxacillin-susceptible strains. The oxazolidinone MICs for other Staphylococcus spp. were < or = 2 micrograms/ml (MIC50, 0.5 to 1 microgram/ml). All enterococci were inhibited by < or = 4 and < or = 2 micrograms of U-100592 and U-100766 per ml, respectively. Against 152 vancomycin-resistant enterococci (five species), both compounds had a narrow range of MICs (0.25 to 2 micrograms/ml) and a MIC90 of 1 microgram/ml. Corynebacterium jeikeium, Bacillus spp., and all tested streptococci were inhibited (< or = 4 micrograms/ml). Members of the family Enterobacteriaceae and other gram-negative bacilli were not susceptible (MIC50, > 64 micrograms/ml) to either oxazolidinone. Three potencies of U-100592 and U-100766 disks were tested (5, 15, and 30 micrograms), and acceptable correlations (r = 0.81 to 0.90) with the measured MICs were observed. Best discrimination of the tentatively susceptible organisms (MICs, < or = 4 micrograms/ml) was demonstrated with the 30-micrograms disk concentration. The oxazolidinones demonstrated a dominant bacteristatic action. These oxazolidinones (U-100592 and U-100766) appear promising for treatment of gram-positive organisms that demonstrate resistance to contemporary therapeutic agents.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference15 articles.
1. Brickner S. J. D. K. Hutchinson M. R. Barbachyn S. A. Garmon K. C. Grega S. K. Hendges P. R. Manninen D. S. Toops D. A. Ulanowicz J. O. Kilburn S. Glickman G. E. Zurenko and C. W. Ford. 1995. Synthesis of U-100592 and U-100766 two new oxazolidinone antibacterial agents in clinical trials for treatment of multiply resistant gram positive infections abstr. 208. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.
2. Brickner S. J. P. R. Manninen D. A. Ulanowicz G. E. Zurenko R. D. Schaadt B. H. Yagi and D. K. Lovasz. 1993. Synthesis and antimicrobial activity of novel multicyclic fused-ring oxazolidinones abstr. 72. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.
3. In vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones;Brumfitt W.;J. Antimicrob. Chemother.,1988
4. Mechanism of action and in vitro studies of DuP 105 and DuP 721, new oxazolidinone antibacterials;Daly J. S.;J. Antimicrob. Chemother.,1988
5. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis;Eustice D. C.;Antimicrob. Agents Chemother.,1988
Cited by
128 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献